Literature DB >> 15632889

How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry.

Daniel G Hackam1, Mary K K Tan, George N Honos, Lawrence A Leiter, Anatoly Langer, Shaun G Goodman.   

Abstract

BACKGROUND: Diabetes mellitus is a major risk factor for atherosclerotic cardiovascular disease. In a large, prospective, practice-based registry (the Vascular Protection Registry), we enrolled patients with vascular disease and/or diabetes, and compared the following features between diabetic and non-diabetic participants: (1) risk factor profiles, (2) utilization of cardioprotective medications, and (3) cardiovascular outcomes in short-term follow-up.
METHODS: Patients were enrolled by participating physicians practicing in family medicine or specialty practices across Canada. The primary outcome was a composite of the first occurrence of any of the following vascular events: myocardial infarction, unstable angina, coronary revascularization, stroke, transient ischemic attack, or death. Patients were stratified according to the presence or absence of cardiovascular disease and diabetes.
RESULTS: In all, 3297 patients were available for analysis (972 [30%] with diabetes but no cardiovascular disease; 899 [27%] with both diabetes and cardiovascular disease; and 1425 [43%] with cardiovascular disease but no diabetes). Most of the measured risk factors were worse for patients with diabetes. Compared to non-diabetic patients, diabetes was associated with substantial undertreatment with cardioprotective medications, including antiplatelet agents, beta blockers, and statins. During a mean follow-up of 10 (SD 3.3) months, patients with both diabetes and cardiovascular disease had the worst prognosis, with the primary outcome occurring at a rate of 16.3 per 100 person-years of follow-up.
CONCLUSIONS: Patient registries provide a powerful tool for examining treatment patterns, risk factors, and outcomes. Patients with both cardiovascular disease and diabetes had the highest rates of adverse vascular outcomes. Possible reasons include relatively worse risk factor profiles and undertreatment with proven cardiovascular medications.

Entities:  

Mesh:

Year:  2004        PMID: 15632889     DOI: 10.1016/j.ahj.2004.04.034

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

Review 1.  Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.

Authors:  David H Fitchett; Lawrence A Leiter; Shaun G Goodman; Anatoly Langer
Journal:  Can J Cardiol       Date:  2006-08       Impact factor: 5.223

2.  Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study.

Authors:  Ehud Ur; Anatoly Langer; Simon W Rabkin; Cristina-Dana Calciu; Lawrence A Leiter
Journal:  Can J Cardiol       Date:  2010-02       Impact factor: 5.223

3.  How many cardiovascular events can be prevented with optimal management of high-risk Canadians?

Authors:  Daniel T Grima; Lawrence A Leiter; Shaun G Goodman; Cheryl L Attard; Chi-Ming Chow; Anatoly Langer
Journal:  Can J Cardiol       Date:  2008-05       Impact factor: 5.223

4.  AGEs/RAGE Promote Osteogenic Differentiation in Rat Bone Marrow-Derived Endothelial Progenitor Cells via MAPK Signaling.

Authors:  Yuping Wang; Chunxia Jiang; Zhongming Shang; Guochun Qiu; Gang Yuan; Kaiqiang Xu; Qingchun Hou; Yanzheng He; Yong Liu
Journal:  J Diabetes Res       Date:  2022-02-01       Impact factor: 4.011

5.  Impact of critical limb ischemia on long-term cardiac mortality in diabetic patients undergoing percutaneous coronary revascularization.

Authors:  Francesco Liistro; Paolo Angioli; Simone Grotti; Rossella Brandini; Italo Porto; Lucia Ricci; Danilo Tacconi; Kenneth Ducci; Giovanni Falsini; Guido Bellandi; Leonardo Bolognese
Journal:  Diabetes Care       Date:  2013-01-22       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.